Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
- Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltdon August 4, 2022 at 2:31 am
Visiongain has published a new report entitled Global Genome Editing Technologies Market, (COVID-19 Impact Analysis):- Market Segment by Type (CRISPR, TALEN, ZFN, Antisense, Others), Market Segment by ...
- CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Researchon August 1, 2022 at 9:42 am
The amazing efficacy of CRISPR-Cas9 for genome editing has led to significant investments in genome engineering. Before clinical use, each variant's pros and cons must be weighed. Researchers are ...
- CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Researchon August 1, 2022 at 5:40 am
The global CRISPR Gene Editing Market was valued USD 1.09 billion in 2021 and is predicted to reach USD 14.80 billion by 2030, increasing at a CAGR of 29.80% from 2022 to 2030. North America dominated ...
- CRISPR Gene Editing Newson July 31, 2022 at 5:01 pm
Scientists have defined with atomic precision a new genome editing tool that is less than half the size of CRISPR-Cas9 -- currently ... of the revolutionary gene technology ...
- CRISPR gene editing may cause permanent damage - studyon July 25, 2022 at 6:43 pm
Several approaches to genome editing have been developed. The best-known technology is called CRISPR-Cas9 gene scissors (CRISPR-associated protein 9), for which the 2020 Nobel Prize in Chemistry ...
- CRISPR gene editing could trigger cancer in the long runon July 25, 2022 at 8:53 am
Researchers from Tel Aviv University warn that CRISPR may not always be safe since rearranging pieces of DNA jeopardizes genomic stability and could promote cancer in the long run.
- CRISPR Genome Editing Market Potential Growth, Top Companies Analysis and Segment Forecasts, 2019 - 2028on July 12, 2022 at 5:00 pm
The CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, more accurate and more efficient than other existing genome editing methods.
via Google News and Bing News